Location History:
- Redmond, WA (US) (2011)
- Bellevue, WA (US) (2022)
Company Filing History:
Years Active: 2011-2022
Title: Yuling Zhang: Innovator in Biotherapeutics
Introduction
Yuling Zhang, an accomplished inventor based in Redmond, WA, has made significant contributions to the field of biotherapeutics. With two patents to her name, Zhang has focused her research on enhancing the production and efficacy of therapeutic molecules through advanced glycosylation techniques.
Latest Patents
Yuling Zhang’s latest inventions showcase her pioneering work in the development of Fc-containing molecules. One of her notable patents, "Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles," addresses the challenges associated with glycosylation in the production of therapeutic antibodies and Fc-fusion molecules. This patent outlines compositions and methods designed to optimize glycosylation maturation and reduce the variability in production processes.
Zhang's other patent, "Methods for refolding of recombinant antibodies," presents an innovative approach to enhance the recovery of preferred forms of IgG proteins. By utilizing a reduction/oxidation coupling reagent along with a chaotropic agent, this invention significantly improves the yield and quality of recombinant IgG proteins.
Career Highlights
Yuling Zhang is currently employed at Amgen Inc., a leading biotechnology company known for its commitment to improving patient outcomes through innovative therapies. Her work at Amgen has been instrumental in advancing biotherapeutics, further solidifying her reputation as a key player in the industry.
Collaborations
Throughout her career, Zhang has collaborated with other notable professionals, including Thomas M. Dillon and Douglas Rehder. These collaborations have enriched her research endeavors and contributed to the successful development of her patents.
Conclusion
Yuling Zhang stands out as an influential inventor in the biotherapeutics domain. Her groundbreaking patents illustrate her dedication to improving therapeutic production processes and the effectiveness of treatments. As she continues her work at Amgen Inc., the impact of her innovations is likely to resonate throughout the biotechnology industry for years to come.